Gennex Laboratories Limited has fulfilled its regulatory obligations by publishing its unaudited financial results for the quarter and nine months ended December 31, 2025, in newspapers as mandated under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance and Publication Details

The company submitted the newspaper publication notice to multiple stock exchanges on February 17, 2026, including BSE Limited (Script Code: 531739), The Ahmedabad Stock Exchange Limited, and The Calcutta Stock Exchange Limited (Scrip Code: 26178). The financial results were published in both Business Standard (English) and Saksham (Telugu - Local) newspapers on Monday, February 16, 2026.

Financial Performance Overview

The unaudited financial results cover both standalone and consolidated figures for the quarter and nine months ended December 31, 2025. These results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on Saturday, February 14, 2026.

Consolidated Results

The consolidated financial results show the company's performance including its subsidiaries. For the quarter ended December 31, 2025, consolidated total income reached ₹10,379.92 thousands compared to ₹4,295.61 thousands in the corresponding quarter of the previous year.

Corporate Governance and Compliance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013. The results have been subjected to limited review by the company's statutory auditors. The company maintains an equity share capital of ₹2,428.48 thousands with a face value of ₹1 per share.

Management and Authorization

The newspaper publication was authorized by Dinesh Kumar Kejriwal, Company Secretary & Compliance Officer (Membership #A19293), and digitally signed on February 17, 2026. The financial results were signed by Arthit Baid, Managing Director (DIN: 01171845), confirming the company's adherence to corporate governance standards.

The complete detailed format of the quarterly financial results is available on the websites of stock exchanges including BSE ( www.bseindia.com ) and on the company's official website ( www.gennexlab.com ) for stakeholder reference.

Source:

Gennex Laboratories Limited announced the appointment of Ms. Khushbu Kachhawa as Additional Non-Executive Independent Women Director, effective February 14, 2026. The appointment was approved by the Board of Directors based on the recommendation of the Nomination & Remuneration Committee and is subject to shareholder approval.

Director Appointment Details

Ms. Khushbu Kachhawa brings professional expertise to the board with her educational background and experience in corporate affairs. The appointment strengthens the company's board composition and governance structure.

Professional Background

Ms. Kachhawa has approximately 5 years of experience in handling business affairs and corporate secretarial matters. She is not related to any Directors or Key Managerial Personnel of the company and fulfills the criteria required under the provisions of the Companies Act, 2013 and the Listing Regulations.

Regulatory Compliance

The appointment has been made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Ms. Kachhawa is not debarred from holding the office of director by virtue of any SEBI order or any other authority. The company has filed the necessary disclosures including Form B under the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Corporate Governance Enhancement

This appointment is part of Gennex Laboratories' ongoing commitment to strengthening its corporate governance framework. The addition of an independent women director aligns with regulatory requirements and enhances board diversity. The pharmaceutical company, which specializes in bulk drugs manufacturing including Guaifenesin and Methocarbamol, continues to focus on maintaining robust governance standards alongside its operational growth.